WO2023109057A1 - S-configuration pro-xylane crystal form compound and preparation method therefor - Google Patents

S-configuration pro-xylane crystal form compound and preparation method therefor Download PDF

Info

Publication number
WO2023109057A1
WO2023109057A1 PCT/CN2022/099659 CN2022099659W WO2023109057A1 WO 2023109057 A1 WO2023109057 A1 WO 2023109057A1 CN 2022099659 W CN2022099659 W CN 2022099659W WO 2023109057 A1 WO2023109057 A1 WO 2023109057A1
Authority
WO
WIPO (PCT)
Prior art keywords
bosein
configuration
crystal compound
crystal
preparation
Prior art date
Application number
PCT/CN2022/099659
Other languages
French (fr)
Chinese (zh)
Inventor
李振朴
丁小妹
方欣
于铁妹
潘俊锋
刘建
Original Assignee
深圳瑞德林生物技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳瑞德林生物技术有限公司 filed Critical 深圳瑞德林生物技术有限公司
Publication of WO2023109057A1 publication Critical patent/WO2023109057A1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Definitions

  • the invention belongs to the technical field of medicine, and in particular relates to an S-configuration Bosein crystal compound and a preparation method thereof.
  • Bosein hydroxypropyltetrahydropyrantriol, which is a glycoprotein mixture derived from xyloside. It was first developed by the French L'Oreal Paris company. , has anti-aging effects. Its structural formula is:
  • Boseine works in two ways. On the one hand, it can stimulate the synthesis of glycosaminoglycans (GAGs), so as to restore the function of the extracellular matrix.
  • GAGs glycosaminoglycans
  • GAGs are networks with strong water absorption capacity. During our aging process, the synthesis of this network It becomes difficult and the water absorption capacity becomes poor, and the skin will lose its plump state when it was young, and Bosein can stimulate the synthesis of glycosaminoglycans GAGs to improve this state; The junction of the dermis plays a role (promoting the synthesis of collagen VII and collagen IV), making the epidermis and dermis fit closer together, and the skin becomes firmer and more elastic.
  • Bosene The preparation method of Bosene can be found in Bioorg.Med.Chem.Lett, 2009, 19:845-849. Since Bose absorbs moisture easily in the air, crystal stability is very important. A crystal form of Bosene is disclosed in the above literature, but the corresponding preparation method is not reported, and the stability of Bosene still needs to be improved.
  • the technical problem to be solved by the present invention is to provide an S-configuration Bosein crystal compound with high stability and a preparation method thereof.
  • the invention provides an S-configuration Bosein crystal compound, the S-configuration Bosein crystal compound is a crystalline hydrate, and its molecular formula is C 8 H 16 O 5 ⁇ H 2 O.
  • the unit cell volume of the Bosein crystal compound is the unit cell volume of the Bosein crystal compound
  • the Bosein crystal compound has a density of 1.288 g/cm 3 .
  • the S-configuration Bosein crystal compound has the characteristics of X-ray powder diffraction spectrum as described in the following table, wherein the error of 2 ⁇ and interplanar spacing is ⁇ 0.2:
  • the present invention also provides a preparation method of an S-configuration Bosein crystal compound, comprising:
  • the ratio of the S-configuration Bosene to water or alcohol solvent is 1 mg: (0.05-0.2) mL.
  • the mixing and dissolving is carried out under heating; the heating temperature is greater than or equal to 50°C.
  • the present invention also provides the application of the above-mentioned S-configuration Bosein crystal compound in the preparation of cosmetics.
  • the invention provides an S-configuration Bosein crystal compound, the S-configuration Bosein crystal compound is a crystalline hydrate, and its molecular formula is C 8 H 16 O 5 ⁇ H 2 O. Compared with the prior art, the S-configuration Bosein crystal compound provided by the present invention has higher stability.
  • Fig. 1 is the molecular structure diagram of the S-configuration Bosein crystal compound obtained in Example 1 of the present invention
  • Figure 2 is a unit cell packing diagram of the S-configuration Bosein crystal compound obtained in Example 1 of the present invention.
  • Fig. 3 is the X-ray powder diffraction pattern of the S-configuration Bosein crystal compound obtained in Example 1 of the present invention
  • Figure 4 is a list of diffraction peaks of the X-ray powder diffraction of the S-configuration Bosein crystal compound obtained in Example 1 of the present invention.
  • the invention provides an S-configuration Bosein crystal compound, the S-configuration Bosein crystal compound is a crystalline hydrate, and its molecular formula is C 8 H 16 O 5 ⁇ H 2 O.
  • the invention adopts the internationally recognized X-ray diffraction method (XRD) to study and characterize the crystal structure of the S-configuration Bosein crystal compound.
  • Equipment Bruker Apex II CCD single crystal X-ray diffractometer.
  • a total of 4845 diffraction points were collected, of which 1672 diffraction points (I>2 ⁇ (I)) were observed and used for structure correction. Diffraction data were corrected for LP factors and empirical absorption.
  • the invention adopts the internationally recognized X-ray powder diffraction method (XRPD) to study and characterize the crystal form of the S-configuration Bosein crystal compound.
  • XRPD X-ray powder diffraction method
  • Measurement conditions and methods scan axis Gonio; start position [°2Th.] 3.0131; end position [°2Th.] 60.0051; step size [°2Th.] 0.0260; scan time per step [s] 93.8400; scan type Continuous; PSD mode scanning; PSD length [°2Th.] 3.35; offset [°2Th.] 0.0000; divergence slit type fixed; divergence slit size [°] 0.4354; sample length [mm] 10.00; measurement temperature [°C] 25.00 ; light pipe target Cu; K-Alpha1 1.54060; K-Alpha2 1.54443; K-Beta 1.39225; K-Alpha2/K-Alpha1 ratio 0.50000; high voltage generator setting 40mA, 45kV; diffractometer type 0000000011191334; goniometer radius [mm] 240.00; diverging slit bull center distance [mm] 100.00; incident light path monochromator No ;Rotate no.
  • the X-ray powder diffraction pattern of the S-configuration Bosein crystal compound provided by the present invention is shown in Figure 3, and has the characteristics of the X-ray powder diffraction pattern described in the table below, wherein the error of 2 ⁇ and interplanar spacing ⁇ 0.2:
  • the S-configuration Bosein crystal compound provided by the invention has relatively high stability.
  • the present invention also provides a preparation method of the above-mentioned S-configuration Bosein crystal form compound, comprising: mixing and dissolving the S-configuration Boseine and water, standing, filtering, and drying to obtain the Bosein crystal form compound.
  • the present invention has no special limitation on the source of all raw materials, and the purity of the compound can reach more than 99%.
  • it is S-configuration Bosene with an HPLC purity of 99.01% obtained by the preparation method described in the literature Bioorg.Med.Chem.Lett, 2009, 19:845-849.
  • the ratio of the S-configuration Boseine to water or alcohol solvent is preferably 1 mg: (0.05-0.2) mL, more preferably 1 mg: (0.08 ⁇ 0.15) mL, more preferably 1mg: 0.1mL;
  • the alcohol solvent is an alcohol solvent well known to those skilled in the art, and there is no special limitation. In the present invention, it is preferably anhydrous alcohol solvent, more preferably anhydrous alcohol solvent.
  • the standing time is preferably more than 20 hours, more preferably equal to or greater than 24 hours. It is necessary to prevent vibration during the static growth of single crystal.
  • the solvent used is an alcohol solvent
  • a non-polar solvent dropwise after dissolving, and leave it to stand after solids appear is preferred;
  • the non-polar solvent is preferably dichloromethane and/or sherwood oil;
  • the time is preferably more than 20h, more preferably equal to or greater than 24h. It is necessary to prevent vibration during the static growth of single crystal.
  • the system is in a non-closed state during the standing process, so when the solvent used is anhydrous alcohol solvent, due to the hygroscopicity of the S-configuration Boseine, it will absorb moisture from the air, thereby obtaining crystals containing crystal water.
  • the washing is preferably an alcohol solvent, more preferably ethanol and/or methanol; the drying is preferably vacuum Drying; the drying temperature is preferably 30°C to 40°C.
  • the present invention also provides an application of the above-mentioned S-configuration Bosein crystal compound in the preparation of cosmetics.
  • the size of 0.230mm ⁇ 0.140mm ⁇ 0.090mm white prismatic crystals prepared according to the method in Example 1 is selected and placed on the glass fiber, and X-ray diffraction analysis is carried out at a temperature of 2969 (2) K to obtain its molecular structure as shown in As shown in Figure 1, the unit cell packing diagram is obtained, as shown in Figure 2.
  • Diffraction data were corrected for LP factors and empirical absorption.
  • the direct method and several rounds of differential Fourier synthesis were used to find all non-hydrogen atoms, and the coordinates of the hydrogen atoms were obtained by geometric hydrogenation. All non-hydrogen atoms in the structure were corrected by full-matrix least squares and anisotropic thermal parameters were used.
  • the S-configuration boson single crystal obtained in embodiment 1 is carried out stability test, obtains following result:
  • the S-configuration Bosein single crystal obtained in Example 1 is mixed with common cosmetic raw materials (water, ethanol, glycerin) at room temperature and miscible, and the properties of the product do not change.
  • Example 1 The S-configuration Bosein single crystal obtained in Example 1 is detected by X-rays, and its X-ray powder diffraction pattern is obtained as shown in Figure 3; the diffraction peak list diagram of its X-ray powder diffraction is obtained as shown in Fig. 4.

Abstract

Provided in the present invention is an S-configuration pro-xylane crystal form compound, which is a crystalline hydrate, and has a molecular formula of C8H16O5·H2O. Compared with the prior art, the S-configuration pro-xylane crystal form compound provided in the present invention has a relatively high stability.

Description

一种S-构型玻色因晶型化合物及其制备方法A kind of S-configuration Bosein crystal compound and preparation method thereof
本申请要求于2021年12月17日提交中国专利局、申请号为202111556250.X、发明名称为“一种S-构型玻色因晶型化合物及其制备方法”的中国专利申请的优先权,其全部内容通过引用结合在本申请中。This application claims the priority of the Chinese patent application submitted to the China Patent Office on December 17, 2021, with the application number 202111556250.X, and the title of the invention "An S-configuration Bosein crystal compound and its preparation method" , the entire contents of which are incorporated in this application by reference.
技术领域technical field
本发明属于医药技术领域,尤其涉及一种S-构型玻色因晶型化合物及其制备方法。The invention belongs to the technical field of medicine, and in particular relates to an S-configuration Bosein crystal compound and a preparation method thereof.
背景技术Background technique
玻色因的INCI(国际化妆品成分命名法)名为羟丙基四氢吡喃三醇,是一种从木糖苷衍生而来的糖蛋白混合物,最早由法国L’Oreal Paris公司研发的化妆品成分,具有抗衰老的功效。其结构式为:The INCI (International Cosmetic Ingredient Nomenclature) name of Bosein is hydroxypropyltetrahydropyrantriol, which is a glycoprotein mixture derived from xyloside. It was first developed by the French L'Oreal Paris company. , has anti-aging effects. Its structural formula is:
Figure PCTCN2022099659-appb-000001
Figure PCTCN2022099659-appb-000001
玻色因可通过以下两方面起作用。一方面可以刺激糖胺聚糖GAGs的合成,从而达到恢复细胞外基质功能的作用,简单来说,糖胺聚糖GAGs就是吸水能力很强的网,在我们衰老的过程中,这个网的合成变得困难,吸水能力变差,肌肤便会丢失年轻时的饱满状态,而玻色因可以激糖胺聚糖GAGs的合成,改善这种状态;另一方面,玻色因可以在表皮层和真皮层交界处发挥作用(促进胶原蛋白VII和胶原蛋白IV的合成),使表皮和真皮贴合更紧密,皮肤变得更紧致、有弹性。Boseine works in two ways. On the one hand, it can stimulate the synthesis of glycosaminoglycans (GAGs), so as to restore the function of the extracellular matrix. Simply put, glycosaminoglycans (GAGs) are networks with strong water absorption capacity. During our aging process, the synthesis of this network It becomes difficult and the water absorption capacity becomes poor, and the skin will lose its plump state when it was young, and Bosein can stimulate the synthesis of glycosaminoglycans GAGs to improve this state; The junction of the dermis plays a role (promoting the synthesis of collagen VII and collagen IV), making the epidermis and dermis fit closer together, and the skin becomes firmer and more elastic.
玻色因的制备方法可参见Bioorg.Med.Chem.Lett,2009,19:845-849。由于玻色因在空气中易吸潮,因此晶型稳定性很重要。上述文献中公开了玻色因的一种晶型,但并未报道相应的制备方法,且玻色因的稳定性仍需要提高。The preparation method of Bosene can be found in Bioorg.Med.Chem.Lett, 2009, 19:845-849. Since Bose absorbs moisture easily in the air, crystal stability is very important. A crystal form of Bosene is disclosed in the above literature, but the corresponding preparation method is not reported, and the stability of Bosene still needs to be improved.
发明内容Contents of the invention
有鉴于此,本发明要解决的技术问题在于提供一种具有较高稳定性的S-构型玻色因晶型化合物及其制备方法。In view of this, the technical problem to be solved by the present invention is to provide an S-configuration Bosein crystal compound with high stability and a preparation method thereof.
本发明提供了一种S-构型玻色因晶型化合物,所述S-构型玻色因晶型化 合物为结晶水合物,其分子式为C 8H 16O 5·H 2O。 The invention provides an S-configuration Bosein crystal compound, the S-configuration Bosein crystal compound is a crystalline hydrate, and its molecular formula is C 8 H 16 O 5 ·H 2 O.
优选的,所述玻色因晶型化合物为单斜晶系,P21空间群,晶胞参数为
Figure PCTCN2022099659-appb-000002
α=90°,β=103.221(4)°,γ=90°。
Preferably, the Bosein compound is a monoclinic crystal system with a space group of P21, and the unit cell parameters are
Figure PCTCN2022099659-appb-000002
α=90°, β=103.221(4)°, γ=90°.
优选的,所述玻色因晶型化合物的晶胞体积
Figure PCTCN2022099659-appb-000003
Preferably, the unit cell volume of the Bosein crystal compound
Figure PCTCN2022099659-appb-000003
优选的,所述玻色因晶型化合物的晶胞中的分子个数Z=2。Preferably, the number of molecules in the unit cell of the Bosein crystal compound is Z=2.
优选的,所述玻色因晶型化合物的密度为1.288g/cm 3Preferably, the Bosein crystal compound has a density of 1.288 g/cm 3 .
优选的,所述S-构型玻色因晶型化合物具有如下表所述的X-射线粉末衍射谱图特征,其中2θ和晶面间距误差±0.2:Preferably, the S-configuration Bosein crystal compound has the characteristics of X-ray powder diffraction spectrum as described in the following table, wherein the error of 2θ and interplanar spacing is ±0.2:
Figure PCTCN2022099659-appb-000004
Figure PCTCN2022099659-appb-000004
本发明还提供了一种S-构型玻色因晶型化合物的制备方法,包括:The present invention also provides a preparation method of an S-configuration Bosein crystal compound, comprising:
将S-构型玻色因与水或醇溶剂混合溶解,静置,过滤,干燥,得到玻色因晶型化合物。Mix and dissolve the S-configuration Bosein with water or alcohol solvent, let stand, filter and dry to obtain the Bosein crystal compound.
优选的,所述S-构型玻色因与水或醇溶剂的比例为1mg:(0.05~0.2)mL。Preferably, the ratio of the S-configuration Bosene to water or alcohol solvent is 1 mg: (0.05-0.2) mL.
优选的,所述混合溶解在加热的条件下进行;所述加热的温度大于等于50℃。Preferably, the mixing and dissolving is carried out under heating; the heating temperature is greater than or equal to 50°C.
本发明还提供了上述S-构型玻色因晶型化合物在制备化妆品中的应用。The present invention also provides the application of the above-mentioned S-configuration Bosein crystal compound in the preparation of cosmetics.
本发明提供了一种S-构型玻色因晶型化合物,所述S-构型玻色因晶型化合物为结晶水合物,其分子式为C 8H 16O 5·H 2O。与现有技术相比,本发明提供的S-构型玻色因晶型化合物具有较高的稳定性。 The invention provides an S-configuration Bosein crystal compound, the S-configuration Bosein crystal compound is a crystalline hydrate, and its molecular formula is C 8 H 16 O 5 ·H 2 O. Compared with the prior art, the S-configuration Bosein crystal compound provided by the present invention has higher stability.
附图说明Description of drawings
图1为本发明实施例1中得到的S-构型玻色因晶型化合物的分子结构图;Fig. 1 is the molecular structure diagram of the S-configuration Bosein crystal compound obtained in Example 1 of the present invention;
图2为本发明实施例1中得到的S-构型玻色因晶型化合物的晶胞堆积图;Figure 2 is a unit cell packing diagram of the S-configuration Bosein crystal compound obtained in Example 1 of the present invention;
图3为本发明实施例1中得到的S-构型玻色因晶型化合物的X-射线粉末 衍射图;Fig. 3 is the X-ray powder diffraction pattern of the S-configuration Bosein crystal compound obtained in Example 1 of the present invention;
图4为本发明实施例1中得到的S-构型玻色因晶型化合物的X-射线粉末衍射的衍射峰列表图。Figure 4 is a list of diffraction peaks of the X-ray powder diffraction of the S-configuration Bosein crystal compound obtained in Example 1 of the present invention.
具体实施方式Detailed ways
下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。The technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only some of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by persons of ordinary skill in the art without making creative efforts belong to the protection scope of the present invention.
本发明提供了一种S-构型玻色因晶型化合物,所述S-构型玻色因晶型化合物为结晶水合物,其分子式为C 8H 16O 5·H 2O。 The invention provides an S-configuration Bosein crystal compound, the S-configuration Bosein crystal compound is a crystalline hydrate, and its molecular formula is C 8 H 16 O 5 ·H 2 O.
进一步具体的,所述S-构型玻色因晶型化合物为单斜晶系,P21空间群,晶胞参数为
Figure PCTCN2022099659-appb-000005
α=90°,β=103.221(4)°,γ=90°。
Further specifically, the S-configuration Bosein compound is a monoclinic crystal system with a space group of P21, and the unit cell parameters are
Figure PCTCN2022099659-appb-000005
α=90°, β=103.221(4)°, γ=90°.
进一步具体的,所述S-构型玻色因晶型化合物的晶胞体积
Figure PCTCN2022099659-appb-000006
所述S-构型玻色因晶型化合物的晶胞中的分子个数Z=2;所述S-构型玻色因晶型化合物的密度为1.288g/cm 3;所述S-构型玻色因晶型化合物中C7原子为S构型。
Further specifically, the unit cell volume of the S-configuration Bosein crystal compound
Figure PCTCN2022099659-appb-000006
The number of molecules in the unit cell of the S-configuration Bosein crystal compound is Z=2; the density of the S-configuration Bosein crystal compound is 1.288g/cm 3 ; the S-configuration The C7 atom in the Bosein crystal compound is in the S configuration.
本发明采用国际上公认的X-射线衍射法(XRD)来研究和表征S-构型玻色因晶型化合物的晶体结构。仪器设备:Bruker Apex II CCD单晶X-ray衍射仪。选取石墨单色化的Mo靶其射线Kα
Figure PCTCN2022099659-appb-000007
Figure PCTCN2022099659-appb-000008
方式扫描,在θ=1.884°~25.082°范围内收集晶体衍射数据,共收集到衍射点4845个,其中可观察衍射(I>2σ(I))1672个,并用于结构修正。衍射数据经LP因子和经验吸收校正。采用直接法,并经数轮差值Fourier合成,找到全部非氢原子,氢原子坐标采用几何加氢法得到。结构中全部非氢原子采用全矩阵最小二乘法修正,并采用各向异性热参数。结构解析精修所用的软件程序为SHELXTL Version 6.14。所述S-构型玻色因晶型化合物的晶体数据参见表1,部分键长参见表2,部分键角参见表3。
The invention adopts the internationally recognized X-ray diffraction method (XRD) to study and characterize the crystal structure of the S-configuration Bosein crystal compound. Equipment: Bruker Apex II CCD single crystal X-ray diffractometer. The ray Kα of the Mo target selected for graphite monochromatization
Figure PCTCN2022099659-appb-000007
by
Figure PCTCN2022099659-appb-000008
The crystal diffraction data were collected in the range of θ=1.884°~25.082°. A total of 4845 diffraction points were collected, of which 1672 diffraction points (I>2σ(I)) were observed and used for structure correction. Diffraction data were corrected for LP factors and empirical absorption. Using the direct method and several rounds of differential Fourier synthesis, all non-hydrogen atoms were found, and the coordinates of the hydrogen atoms were obtained by geometric hydrogenation. All non-hydrogen atoms in the structure were corrected by full-matrix least squares, and anisotropic thermal parameters were used. The software program used for structural analysis and refinement is SHELXTL Version 6.14. See Table 1 for the crystal data of the S-configuration Bosein crystal compound, see Table 2 for some bond lengths, and see Table 3 for some bond angles.
表1 S-构型玻色因晶型化合物的晶体数据Table 1 Crystal data of S-configuration Bosein compound
Figure PCTCN2022099659-appb-000009
Figure PCTCN2022099659-appb-000009
Figure PCTCN2022099659-appb-000010
Figure PCTCN2022099659-appb-000010
表2 S-构型玻色因晶型化合物晶体中部分键长Table 2 Some bond lengths in crystals of S-configuration Bosein compounds
Figure PCTCN2022099659-appb-000011
Figure PCTCN2022099659-appb-000011
表3 S-构型玻色因晶型化合物晶体中部分键角Table 3 Some bond angles in crystals of S-configuration Bosein compounds
原子-原子-原子atom-atom-atom 键角(°)Bond angle (°) 原子-原子-原子atom-atom-atom 键角(°)Bond angle (°)
C(1)-O(1)-C(5)C(1)-O(1)-C(5) 112.6(3)112.6(3) C(3)-C(4)-C(5)C(3)-C(4)-C(5) 111.9(4)111.9(4)
O(1)-C(1)-C(2)O(1)-C(1)-C(2) 110.1(4)110.1(4) O(1)-C(5)-C(6)O(1)-C(5)-C(6) 108.1(4)108.1(4)
O(2)-C(2)-C(3)O(2)-C(2)-C(3) 111.1(4)111.1(4) O(1)-C(5)-C(4)O(1)-C(5)-C(4) 108.3(4)108.3(4)
O(2)-C(2)-C(1)O(2)-C(2)-C(1) 110.9(4)110.9(4) C(6)-C(5)-C(4)C(6)-C(5)-C(4) 113.5(4)113.5(4)
C(3)-C(2)-C(1)C(3)-C(2)-C(1) 111.0(4)111.0(4) C(7)-C(6)-C(5)C(7)-C(6)-C(5) 115.2(4)115.2(4)
C(2)-C(3)-C(4)C(2)-C(3)-C(4) 110.9(4)110.9(4) O(4)-C(7)-C(8)O(4)-C(7)-C(8) 107.8(4)107.8(4)
O(3)-C(4)-C(3)O(3)-C(4)-C(3) 107.4(4)107.4(4) O(4)-C(7)-C(6)O(4)-C(7)-C(6) 111.0(4)111.0(4)
O(3)-C(4)-C(5)O(3)-C(4)-C(5) 110.5(4)110.5(4) C(8)-C(7)-C(6)C(8)-C(7)-C(6) 113.0(5)113.0(5)
O(003)-C(3)-C(2)O(003)-C(3)-C(2) 107.1(4)107.1(4) O(003)-C(3)-C(4)O(003)-C(3)-C(4) 111.0(4)111.0(4)
本发明采用国际上公认的X射线粉末衍射法(XRPD)来研究和表征S-构型玻色因晶型化合物的晶型。The invention adopts the internationally recognized X-ray powder diffraction method (XRPD) to study and characterize the crystal form of the S-configuration Bosein crystal compound.
仪器设备:RIGAKU TTR III型X射线粉末衍射仪。Equipment: RIGAKU TTR III type X-ray powder diffractometer.
测定条件与方法:扫描轴Gonio;起始位置[°2Th.]3.0131;终点位置[°2Th.]60.0051;步长[°2Th.]0.0260;扫描每步时间[s]93.8400;扫描类型Continuous;PSD模式扫描;PSD长度[°2Th.]3.35;偏量[°2Th.]0.0000;发散狭缝类型固定;发散狭缝大小[°]0.4354;样品长度[mm]10.00;测量温度[℃]25.00;光管靶材Cu;K-Alpha1
Figure PCTCN2022099659-appb-000012
1.54060;K-Alpha2
Figure PCTCN2022099659-appb-000013
1.54443;K-Beta
Figure PCTCN2022099659-appb-000014
1.39225;K-Alpha2/K-Alpha1比0.50000;高压发生器设置40mA,45kV;衍射仪类型0000000011191334;测角仪半径[mm]240.00;发散狭缝靶心间距[mm]100.00;入射光路单色器否;旋转否。
Measurement conditions and methods: scan axis Gonio; start position [°2Th.] 3.0131; end position [°2Th.] 60.0051; step size [°2Th.] 0.0260; scan time per step [s] 93.8400; scan type Continuous; PSD mode scanning; PSD length [°2Th.] 3.35; offset [°2Th.] 0.0000; divergence slit type fixed; divergence slit size [°] 0.4354; sample length [mm] 10.00; measurement temperature [°C] 25.00 ; light pipe target Cu; K-Alpha1
Figure PCTCN2022099659-appb-000012
1.54060; K-Alpha2
Figure PCTCN2022099659-appb-000013
1.54443; K-Beta
Figure PCTCN2022099659-appb-000014
1.39225; K-Alpha2/K-Alpha1 ratio 0.50000; high voltage generator setting 40mA, 45kV; diffractometer type 0000000011191334; goniometer radius [mm] 240.00; diverging slit bull center distance [mm] 100.00; incident light path monochromator No ;Rotate no.
本发明提供的S-构型玻色因晶型化合物的X-射线粉末衍射图如图3所示,具有如下表所述的X-射线粉末衍射谱图特征,其中2θ和晶面间距误差±0.2:The X-ray powder diffraction pattern of the S-configuration Bosein crystal compound provided by the present invention is shown in Figure 3, and has the characteristics of the X-ray powder diffraction pattern described in the table below, wherein the error of 2θ and interplanar spacing ± 0.2:
Figure PCTCN2022099659-appb-000015
Figure PCTCN2022099659-appb-000015
本发明提供的S-构型玻色因晶型化合物具有较高的稳定性。The S-configuration Bosein crystal compound provided by the invention has relatively high stability.
本发明还提供了一种上述S-构型玻色因晶型化合物的制备方法,包括:将S-构型玻色因与水混合溶解,静置,过滤,干燥,得到玻色因晶型化合物。The present invention also provides a preparation method of the above-mentioned S-configuration Bosein crystal form compound, comprising: mixing and dissolving the S-configuration Boseine and water, standing, filtering, and drying to obtain the Bosein crystal form compound.
其中,本发明对所有原料的来源并没有特殊的限制,化合物纯度达99%以上即可;所述S-构型玻色因优选为HPLC纯度99%以上的S-构型玻色因;在本发明提供的实施例中,具体为由文献Bioorg.Med.Chem.Lett,2009,19:845-849中所述的制备方法获得的HPLC纯度99.01%的S-构型玻色因。Wherein, the present invention has no special limitation on the source of all raw materials, and the purity of the compound can reach more than 99%. In the examples provided by the present invention, specifically, it is S-configuration Bosene with an HPLC purity of 99.01% obtained by the preparation method described in the literature Bioorg.Med.Chem.Lett, 2009, 19:845-849.
将S-构型玻色因与水或醇溶剂混合溶解;所述S-构型玻色因与水或醇溶剂的比例优选为1mg:(0.05~0.2)mL,更优选为1mg:(0.08~0.15)mL,再 优选为1mg:0.1mL;所述醇溶剂为本领域技术人员熟知的醇溶剂即可,并无特殊的限制,在本发明中优选为无水醇溶剂,更优选为无水甲醇、无水乙醇与无水正丁醇中的一种或多种;所述混合溶解优选在加热搅拌的条件下进行;所述加热搅拌的温度优选大于等于50℃;所述加热搅拌的时间优选为2~10min,更优选为4~7min,至固体溶解并澄清;在本发明提供的实施例具体为加热搅拌5min。Mix and dissolve the S-configuration Boseine with water or alcohol solvent; the ratio of the S-configuration Boseine to water or alcohol solvent is preferably 1 mg: (0.05-0.2) mL, more preferably 1 mg: (0.08 ~0.15) mL, more preferably 1mg: 0.1mL; The alcohol solvent is an alcohol solvent well known to those skilled in the art, and there is no special limitation. In the present invention, it is preferably anhydrous alcohol solvent, more preferably anhydrous alcohol solvent. One or more of water methanol, absolute ethanol and anhydrous n-butanol; the mixing and dissolving is preferably carried out under the condition of heating and stirring; the temperature of the heating and stirring is preferably greater than or equal to 50°C; the heating and stirring The time is preferably 2-10 minutes, more preferably 4-7 minutes, until the solid is dissolved and clarified; in the example provided by the present invention, it is specifically heating and stirring for 5 minutes.
混合溶解后,优选冷却至室温,静置;静置的时间优选为20h以上,更优选静置等于大于24h。静置生长单晶的过程中需防止震动。After mixing and dissolving, it is preferably cooled to room temperature and allowed to stand; the standing time is preferably more than 20 hours, more preferably equal to or greater than 24 hours. It is necessary to prevent vibration during the static growth of single crystal.
当所用溶剂为醇溶剂时,在溶解后优选还滴加非极性溶剂,至固体出现后,静置;所述非极性溶剂优选为二氯甲烷和/或石油醚;所述静置的时间优选为20h以上,更优选静置等于大于24h。静置生长单晶的过程中需防止震动。When the solvent used is an alcohol solvent, it is preferred to add a non-polar solvent dropwise after dissolving, and leave it to stand after solids appear; the non-polar solvent is preferably dichloromethane and/or sherwood oil; The time is preferably more than 20h, more preferably equal to or greater than 24h. It is necessary to prevent vibration during the static growth of single crystal.
在静置的过程中体系处于非密闭状态,因此在所用溶剂为无水醇溶剂时,由于S-构型玻色因的吸湿性,会从空气中吸湿,从而得到含有结晶水的晶体。The system is in a non-closed state during the standing process, so when the solvent used is anhydrous alcohol solvent, due to the hygroscopicity of the S-configuration Boseine, it will absorb moisture from the air, thereby obtaining crystals containing crystal water.
静置后,析出晶体,过滤,优选洗涤、干燥后,得到S-构型玻色因晶型化合物;所述洗涤优选采用醇溶剂,更优选为乙醇和/或甲醇;所述干燥优选为真空干燥;所述干燥的温度优选为30℃~40℃。After standing still, crystals are precipitated, filtered, preferably washed and dried, to obtain the S-configuration Bosein crystal compound; the washing is preferably an alcohol solvent, more preferably ethanol and/or methanol; the drying is preferably vacuum Drying; the drying temperature is preferably 30°C to 40°C.
本发明还提供了一种上述S-构型玻色因晶型化合物在制备化妆品中的应用。The present invention also provides an application of the above-mentioned S-configuration Bosein crystal compound in the preparation of cosmetics.
为了进一步说明本发明,以下结合实施例对本发明提供的一种S-构型玻色因晶型化合物及其制备方法进行详细描述。In order to further illustrate the present invention, an S-configuration Bosein crystal compound provided by the present invention and its preparation method are described in detail below in conjunction with the examples.
以下实施例中所用的试剂均为市售。The reagents used in the following examples are all commercially available.
实施例1Example 1
将10mgS-构型玻色因固体加入到1mL纯化水中,在50℃下搅拌5min至固体全部溶解并澄清,停止加热并静止冷却至室温,静止放置24h(在单晶生长过程中防止震动)。析晶,过滤,乙醇洗涤,40℃真空干燥,得S-构型玻色因单晶9mg,收率90%。Add 10 mg of S-configuration Bosein solid to 1 mL of purified water, stir at 50°C for 5 min until the solid is completely dissolved and clear, stop heating and let it cool down to room temperature for 24 h (avoid vibration during single crystal growth). Crystallize, filter, wash with ethanol, and dry under vacuum at 40°C to obtain 9 mg of S-configuration Bosein single crystal, with a yield of 90%.
实施例2Example 2
将15mgS-构型玻色因固体加入到2mL无水乙醇中,在50℃下搅拌5min至固体全部溶解并澄清,停止加热并静止冷却至室温,静止放置24h(在单晶生长过程中防止震动)。析晶,过滤,洗涤,真空干燥,得S-构型玻色因单晶 14.3mg,收率95%。Add 15 mg of S-configuration Bosein solid to 2 mL of absolute ethanol, stir at 50°C for 5 min until the solid is completely dissolved and clear, stop heating and let it cool down to room temperature, and let it stand still for 24 hours (prevent vibration during single crystal growth) ). Crystallization, filtration, washing, and vacuum drying yielded 14.3 mg of S-configuration Bosene single crystal with a yield of 95%.
实施例3Example 3
将10mgS-构型玻色因固体加入到2mL无水甲醇中,在50℃下搅拌5min至固体全部溶解并澄清,停止加热并静止冷却至室温,静止放置24h(在单晶生长过程中防止震动)。析晶,过滤,乙醇洗涤,40℃真空干燥,得S-构型玻色因单晶9.4mg,收率94%。Add 10mg of S-configuration Bosein solid to 2mL of anhydrous methanol, stir at 50°C for 5min until the solid is completely dissolved and clear, stop heating and let it cool down to room temperature, and let it stand still for 24h (prevent vibration during single crystal growth) ). Crystallize, filter, wash with ethanol, and dry under vacuum at 40°C to obtain 9.4 mg of S-configuration Bosene single crystal, with a yield of 94%.
实施例4Example 4
将15mgS-构型玻色因固体加入到2mL正丁醇中,在50℃下搅拌5min至固体全部溶解并澄清,停止加热并静止冷却至室温,静止放置24h(在单晶生长过程中防止震动)。析晶,过滤,乙醇洗涤,40℃真空干燥,得S-构型玻色因单晶13.8mg,收率92%。Add 15 mg of S-configuration Bosein solid to 2 mL of n-butanol, stir at 50°C for 5 min until the solid is completely dissolved and clear, stop heating and let it cool down to room temperature, and let it stand still for 24 hours (prevent vibration during single crystal growth) ). Crystallize, filter, wash with ethanol, and dry under vacuum at 40°C to obtain 13.8 mg of S-configuration Bosene single crystal, with a yield of 92%.
实施例5Example 5
将10mgS-构型玻色因固体加入到2mL无水甲醇中,在-20℃条件下静止放置24h(在单晶生长过程中防止震动)。析晶,过滤,洗涤,40℃真空干燥,得S-构型玻色因单晶8.2mg,收率82%。Add 10mg of S-configuration Bosein solid to 2mL of anhydrous methanol, and place it statically at -20°C for 24h (avoid vibration during single crystal growth). Crystallize, filter, wash, and dry under vacuum at 40°C to obtain 8.2 mg of S-configuration Bosene single crystal, with a yield of 82%.
实施例6Example 6
将10mgS-构型玻色因固体加入到2mL无水甲醇中,缓慢搅拌下滴加二氯甲烷,直至固体出现,之后继续静置24h(在单晶生长过程中防止震动)。析晶,过滤,洗涤,40℃真空干燥,得S-构型玻色因单晶8.6mg,收率86%。Add 10 mg of S-configuration Bosein solid to 2 mL of anhydrous methanol, add dichloromethane dropwise under slow stirring until the solid appears, and then continue to stand for 24 h (to prevent vibration during the growth of the single crystal). Crystallize, filter, wash, and dry under vacuum at 40°C to obtain 8.6 mg of S-configuration Bosene single crystal, with a yield of 86%.
实施例7Example 7
将10mgS-构型玻色因固体加入到2mL无水甲醇中,缓慢搅拌下滴加石油醚,直至固体出现,之后继续静置24h(在单晶生长过程中防止震动)。析晶,过滤,洗涤,40℃真空干燥,得S-构型玻色因单晶8.5mg,收率85%。Add 10 mg of S-configuration Bosein solid to 2 mL of anhydrous methanol, add petroleum ether dropwise under slow stirring until the solid appears, and then continue to stand for 24 hours (to prevent vibration during the growth of single crystal). Crystallize, filter, wash, and vacuum-dry at 40°C to obtain 8.5 mg of S-configuration Bosene single crystal, with a yield of 85%.
选取依据实施例1中方法制得的尺寸为0.230mm×0.140mm×0.090mm白色棱柱状晶体安置在玻璃纤维上,在2969(2)K温度下进行X射线衍射分析,得到其分子结构图如图1所示,得到其晶胞堆积图,如图2所示。单晶X射线衍射仪上用石墨单色化的MoKa
Figure PCTCN2022099659-appb-000016
射线以
Figure PCTCN2022099659-appb-000017
方式扫描,在θ=1.884°~25.082°范围内收集晶体衍射数据,共收集到衍射点4845个,其中可观察衍射(I>2σ(I))1672个,并用于结构修正。衍射数据经LP因子和经验吸收校正。采用直接法,并经数轮差值Fourier合成,找到全部非氢原子,氢 原子坐标采用几何加氢法得到。结构中全部非氢原子采用全矩阵最小二乘法修正,并采用各向异性热参数。
The size of 0.230mm × 0.140mm × 0.090mm white prismatic crystals prepared according to the method in Example 1 is selected and placed on the glass fiber, and X-ray diffraction analysis is carried out at a temperature of 2969 (2) K to obtain its molecular structure as shown in As shown in Figure 1, the unit cell packing diagram is obtained, as shown in Figure 2. MoKa monochromated with graphite on a single crystal X-ray diffractometer
Figure PCTCN2022099659-appb-000016
ray to
Figure PCTCN2022099659-appb-000017
The crystal diffraction data were collected in the range of θ=1.884°~25.082°. A total of 4845 diffraction points were collected, of which 1672 diffraction points (I>2σ(I)) were observed and used for structure correction. Diffraction data were corrected for LP factors and empirical absorption. The direct method and several rounds of differential Fourier synthesis were used to find all non-hydrogen atoms, and the coordinates of the hydrogen atoms were obtained by geometric hydrogenation. All non-hydrogen atoms in the structure were corrected by full-matrix least squares and anisotropic thermal parameters were used.
所述S-构型玻色因晶型化合物的晶体数据参见表1,部分键长参见表2,部分键角参见表3。See Table 1 for the crystal data of the S-configuration Bosein crystal compound, see Table 2 for some bond lengths, and see Table 3 for some bond angles.
表1 S-构型玻色因晶型化合物的晶体数据Table 1 Crystal data of S-configuration Bosein compound
Figure PCTCN2022099659-appb-000018
Figure PCTCN2022099659-appb-000018
表2 S-构型玻色因晶型化合物晶体中部分键长Table 2 Some bond lengths in crystals of S-configuration Bosein compounds
Figure PCTCN2022099659-appb-000019
Figure PCTCN2022099659-appb-000019
表3 S-构型玻色因晶型化合物晶体中部分键角Table 3 Some bond angles in crystals of S-configuration Bosein compounds
原子-原子-原子atom-atom-atom 键角(°)Bond angle (°) 原子-原子-原子atom-atom-atom 键角(°)Bond angle (°)
C(1)-O(1)-C(5)C(1)-O(1)-C(5) 112.6(3)112.6(3) C(3)-C(4)-C(5)C(3)-C(4)-C(5) 111.9(4)111.9(4)
O(1)-C(1)-C(2)O(1)-C(1)-C(2) 110.1(4)110.1(4) O(1)-C(5)-C(6)O(1)-C(5)-C(6) 108.1(4)108.1(4)
O(2)-C(2)-C(3)O(2)-C(2)-C(3) 111.1(4)111.1(4) O(1)-C(5)-C(4)O(1)-C(5)-C(4) 108.3(4)108.3(4)
O(2)-C(2)-C(1)O(2)-C(2)-C(1) 110.9(4)110.9(4) C(6)-C(5)-C(4)C(6)-C(5)-C(4) 113.5(4)113.5(4)
C(3)-C(2)-C(1)C(3)-C(2)-C(1) 111.0(4)111.0(4) C(7)-C(6)-C(5)C(7)-C(6)-C(5) 115.2(4)115.2(4)
C(2)-C(3)-C(4)C(2)-C(3)-C(4) 110.9(4)110.9(4) O(4)-C(7)-C(8)O(4)-C(7)-C(8) 107.8(4)107.8(4)
O(3)-C(4)-C(3)O(3)-C(4)-C(3) 107.4(4)107.4(4) O(4)-C(7)-C(6)O(4)-C(7)-C(6) 111.0(4)111.0(4)
O(3)-C(4)-C(5)O(3)-C(4)-C(5) 110.5(4)110.5(4) C(8)-C(7)-C(6)C(8)-C(7)-C(6) 113.0(5)113.0(5)
O(003)-C(3)-C(2)O(003)-C(3)-C(2) 107.1(4)107.1(4) O(003)-C(3)-C(4)O(003)-C(3)-C(4) 111.0(4)111.0(4)
对实施例1中得到的S-构型玻色因单晶进行稳定性试验,得到如下结果:The S-configuration boson single crystal obtained in embodiment 1 is carried out stability test, obtains following result:
2~8℃下,密封保存半年,外观无明显变化,无明显吸潮现象,检测后产品性质,旋光度未改变;At 2-8°C, sealed and stored for half a year, there is no obvious change in appearance, no obvious moisture absorption, and the properties and optical rotation of the product have not changed after testing;
20℃下,48h内外观无明显变化,无明显吸潮现象,检测后产品性质,旋光度未改变;At 20°C, there is no obvious change in appearance within 48 hours, no obvious moisture absorption phenomenon, and the product properties and optical rotation have not changed after testing;
40℃下,24h内外观无明显变化,无明显吸潮现象,检测后产品性质,旋光度未改变。At 40°C, there is no obvious change in appearance within 24 hours, no obvious moisture absorption phenomenon, and the product properties and optical rotation have not changed after testing.
50℃下,8h内外观无明显变化,无明显吸潮现象,检测后产品性质,旋光度未改变。At 50°C, there is no obvious change in appearance within 8 hours, no obvious moisture absorption phenomenon, and the product properties and optical rotation have not changed after testing.
应用性能:Application performance:
将实施例1中得到的S-构型玻色因单晶在常温下与常见化妆品原料(水,乙醇,甘油)混合后互溶,且产品性质不发生改变。The S-configuration Bosein single crystal obtained in Example 1 is mixed with common cosmetic raw materials (water, ethanol, glycerin) at room temperature and miscible, and the properties of the product do not change.
利用上述方法对实施例2~7中得到的S-构型玻色因单晶进行检测,得到结果与实施例1相同,确认得到的为同一晶型化合物。The S-configuration Bosein single crystals obtained in Examples 2 to 7 were detected by the above method, and the results obtained were the same as those in Example 1, and it was confirmed that the obtained compounds were of the same crystal form.
利用X射线对实施例1中得到的S-构型玻色因单晶进行检测,得到其X-射线粉末衍射图如图3所示;得到其X-射线粉末衍射的衍射峰列表图如图4所示。The S-configuration Bosein single crystal obtained in Example 1 is detected by X-rays, and its X-ray powder diffraction pattern is obtained as shown in Figure 3; the diffraction peak list diagram of its X-ray powder diffraction is obtained as shown in Fig. 4.

Claims (10)

  1. 一种S-构型玻色因晶型化合物,其特征在于,所述S-构型玻色因晶型化合物为结晶水合物,其分子式为C 8H 16O 5·H 2O。 An S-configuration Bosein crystal compound, characterized in that the S-configuration Bosein crystal compound is a crystalline hydrate, and its molecular formula is C 8 H 16 O 5 ·H 2 O.
  2. 根据权利要求1所述的S-构型玻色因晶型化合物,其特征在于,所述玻色因晶型化合物为单斜晶系,P21空间群,晶胞参数为
    Figure PCTCN2022099659-appb-100001
    Figure PCTCN2022099659-appb-100002
    α=90°,β=103.221(4)°,γ=90°。
    The S-configuration Bosein crystal compound according to claim 1, wherein the Bosein crystal compound is a monoclinic crystal system, P21 space group, and the unit cell parameter is
    Figure PCTCN2022099659-appb-100001
    Figure PCTCN2022099659-appb-100002
    α=90°, β=103.221(4)°, γ=90°.
  3. 根据权利要求1所述的S-构型玻色因晶型化合物,其特征在于,所述玻色因晶型化合物的晶胞体积
    Figure PCTCN2022099659-appb-100003
    The S-configuration Bosein crystal compound according to claim 1, wherein the unit cell volume of the Bosein crystal compound is
    Figure PCTCN2022099659-appb-100003
  4. 根据权利要求1所述的S-构型玻色因晶型化合物,其特征在于,所述玻色因晶型化合物的晶胞中的分子个数Z=2。The S-configuration Bosein crystal compound according to claim 1, characterized in that the number of molecules in the unit cell of the Bosein crystal compound is Z=2.
  5. 根据权利要求1所述的S-构型玻色因晶型化合物,其特征在于,所述玻色因晶型化合物的密度为1.288g/cm 3The S-configuration Bosein crystal compound according to claim 1, characterized in that the density of the Bosein crystal compound is 1.288 g/cm 3 .
  6. 根据权利要求1所述的S-构型玻色因晶型化合物,其特征在于,所述S-构型玻色因晶型化合物具有如下表所述的X-射线粉末衍射谱图特征,其中2θ和晶面间距误差±0.2:The S-configuration Bosein crystal form compound according to claim 1, wherein the S-configuration Bosein crystal form compound has the X-ray powder diffraction spectrum characteristics as described in the following table, wherein 2θ and interplanar spacing error ±0.2:
    Figure PCTCN2022099659-appb-100004
    Figure PCTCN2022099659-appb-100004
  7. 一种S-构型玻色因晶型化合物的制备方法,其特征在于,包括:A method for preparing an S-configuration Bosein crystal compound, characterized in that it comprises:
    将S-构型玻色因与水或醇溶剂混合溶解,静置,过滤,干燥,得到玻色因晶型化合物。Mix and dissolve the S-configuration Bosein with water or alcohol solvent, let stand, filter and dry to obtain the Bosein crystal compound.
  8. 根据权利要求7所述的制备方法,其特征在于,所述S-构型玻色因与水或醇溶剂的比例为1mg:(0.05~0.2)mL。The preparation method according to claim 7, characterized in that the ratio of the S-configuration Bosene to water or alcohol solvent is 1 mg: (0.05-0.2) mL.
  9. 根据权利要求7所述的制备方法,其特征在于,所述混合溶解在加热的条件下进行;所述加热的温度大于等于50℃。The preparation method according to claim 7, characterized in that the mixing and dissolving is carried out under the condition of heating; the heating temperature is greater than or equal to 50°C.
  10. 权利要求1~6任意一项所述的S-构型玻色因晶型化合物或权利要求7~9任意一项制备方法所制备的S-构型玻色因晶型化合物在制备化妆品中的应用。The S-configuration Bosein crystal compound described in any one of claims 1 to 6 or the S-configuration Bosein crystal compound prepared by the preparation method of any one of claims 7 to 9 in the preparation of cosmetics application.
PCT/CN2022/099659 2021-12-17 2022-06-20 S-configuration pro-xylane crystal form compound and preparation method therefor WO2023109057A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111556250.XA CN114105923A (en) 2021-12-17 2021-12-17 S-configuration vitronectin crystal compound and preparation method thereof
CN202111556250.X 2021-12-17

Publications (1)

Publication Number Publication Date
WO2023109057A1 true WO2023109057A1 (en) 2023-06-22

Family

ID=80365963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/099659 WO2023109057A1 (en) 2021-12-17 2022-06-20 S-configuration pro-xylane crystal form compound and preparation method therefor

Country Status (2)

Country Link
CN (1) CN114105923A (en)
WO (1) WO2023109057A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114105923A (en) * 2021-12-17 2022-03-01 深圳瑞德林生物技术有限公司 S-configuration vitronectin crystal compound and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN202041033352A (en) * 2020-08-04 2020-10-02
CN113735811A (en) * 2021-11-03 2021-12-03 深圳瑞德林生物技术有限公司 Method for synthesizing vitrochromic factor through acylation protection and reduction
CN114105923A (en) * 2021-12-17 2022-03-01 深圳瑞德林生物技术有限公司 S-configuration vitronectin crystal compound and preparation method thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN202041033352A (en) * 2020-08-04 2020-10-02
CN113735811A (en) * 2021-11-03 2021-12-03 深圳瑞德林生物技术有限公司 Method for synthesizing vitrochromic factor through acylation protection and reduction
CN114105923A (en) * 2021-12-17 2022-03-01 深圳瑞德林生物技术有限公司 S-configuration vitronectin crystal compound and preparation method thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAVEZZA, A. ; BOULLE, C. ; GUEGUINIAT, A. ; PICHAUD, P. ; TROUILLE, S. ; RICARD, L. ; DALKO-CSIBA, M.: "Synthesis of Pro-Xylane™: A new biologically active C-glycoside in aqueous media", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 19, no. 3, 1 February 2009 (2009-02-01), Amsterdam NL , pages 845 - 849, XP025925835, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2008.12.037 *
DI, LEIQIN ET AL.: "Decipher the "Black Box" of L’ORéAL’s Pro-Xylane", JOURNAL OF LESHAN NORMAL UNIVERSITY, vol. 36, no. 12, 6 July 2021 (2021-07-06), XP009547192 *
FANG, DIANLI ET AL.: "Exploring the Structure of Pro-Xylane", GUANGDONG CHEMICAL INDUSTRY, vol. 48, no. 4, 30 April 2021 (2021-04-30), XP009547200 *

Also Published As

Publication number Publication date
CN114105923A (en) 2022-03-01

Similar Documents

Publication Publication Date Title
CN103476770B (en) Salts and polymorphic forms of afatinib
CN105753789B (en) The eutectic and preparation method thereof of olaparib and urea
RU2631321C2 (en) Crystalline form i of tyrosine kinase inhibitor dicaletat and method for its preparation
JP6720280B2 (en) Novel abexinostat salts, related crystalline forms, methods for their preparation and pharmaceutical compositions containing them
CN102046175A (en) Substituted heterocycle fused gamma-carbolines solid
TR201816159T4 (en) Crystal forms of a purine derivative.
JP2014530805A (en) Crystal form of azilsartan and its production and use
WO2023109057A1 (en) S-configuration pro-xylane crystal form compound and preparation method therefor
WO2016091221A1 (en) Salt of pyrrolo[2,3-d]pyrimidine compound and novel polymorph of salt
CN111303100B (en) Hydrate of michelia lactone dimethylamine fumarate, preparation method and application thereof
BR112013029706A2 (en) rifaximin polymorph and process for its preparation
CN104478815A (en) Multiple salts of 2-(5-bromo-4-(4-cyclopropylnaphthyl-1-yl)-4H-1,2,4-triazolyl-3-ylthio)acetic acid, and crystal forms and preparation method thereof
CN109134581A (en) Three water dexamethasone sodium phosphate compounds of one kind and its drug combination preparation
KR101777632B1 (en) Crystalline Forms of Beraprost Sodium and Process of Preparing the Same
CN109824608B (en) Apabetalone crystal form and preparation method thereof
CN107663166A (en) Lome Tapai and its production and use
BR112021010975A2 (en) CRYSTALLINE FORMS OF 1-[(3R,4S)-4-CYANOTETRAHYDROPYRAN-3-IL]-3-[(2-FLUORO-6-METOXY-4-PYRIDYL)AMINO]PYRAZOLE-4-CARBOXAMIDE
CN113929630B (en) Gefitinib drug co-crystal
TWI727517B (en) Beraprost-314d crystals and methods for preparation thereof
WO2023143090A1 (en) Novel crystalline form of apalutamide solvate and preparation method therefor
CN114685466B (en) Acetinib eutectic salt
CN103819469A (en) Crystal form of dasatinib and preparation method for crystal form of dasatinib
CN114276350B (en) Ketorolac and phenazine eutectic and preparation method thereof
CN104513201B (en) Crystal of pixantrone maleate
CN114685433B (en) Apolitinib vanillic acid eutectic salt and preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22905823

Country of ref document: EP

Kind code of ref document: A1